Skip to content
OpenCapital
Get started

Arcutis Biotherapeutics, Inc. ARQT Cash, cash equivalents, restricted cash and marketable securities

Other financials

Income statement

See full
Revenue$105.4M+60.1%
Gross profit$95.6M+67.7%
Operating income-$9.1M+62.9%
Net income-$11.3M+54.9%
EPS (diluted)-$0.09+55.0%

Balance sheet

See full
Cash & equivalents$35.1M-34.7%
Total debt$114.7M+3.5%
Total equity$189.6M+32.9%
Total assets$460.0M+33.7%

Cash flow

See full
Operating cash flow$2.2M+107%
CapEx--100%
Free cash flow$2.2M+107%

Valuation

See full
Market cap$3.29B+57.5%

Profitability

See full
Gross margin90.9%+2.5pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.6×-0.2×
Current ratio2.7×-0.9×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept arqt:CashCashEquivalentsAndMarketableSecurities.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s cash, cash equivalents, restricted cash and marketable securities?
Arcutis Biotherapeutics, Inc. (ARQT) reported cash, cash equivalents, restricted cash and marketable securities of $224.3M in Q1 2026.
How has Arcutis Biotherapeutics, Inc.'s cash, cash equivalents, restricted cash and marketable securities changed year-over-year?
Arcutis Biotherapeutics, Inc.'s cash, cash equivalents, restricted cash and marketable securities increased by 12.9% year-over-year, from $198.7M to $224.3M.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s cash, cash equivalents, restricted cash and marketable securities?
Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s cash, cash equivalents, restricted cash and marketable securities has grown at a -5.0% compound annual growth rate (CAGR), from $286M to $221.3M.